Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Effect Of Cediranib, Temozolamide And Radiotherapy In U87 Gbm Wtegfr And Egfrviii-Expressing Xenografts, P. Wachsberger, R. Y, Lawrence, Y. Liu, B. Andersen, A. P. Dicker
Effect Of Cediranib, Temozolamide And Radiotherapy In U87 Gbm Wtegfr And Egfrviii-Expressing Xenografts, P. Wachsberger, R. Y, Lawrence, Y. Liu, B. Andersen, A. P. Dicker
Bodine Journal
Introduction: Glioblastomas (GBM) frequently overexpress the epidermal growth factor receptor (wtEGFR) or its mutant, EGFRvIII contributing to radioresistance. New treatment strategies for GBM include blockade of EGFR signaling and angiogenesis. Cediranib (CD) is a highly potent VEGFR-2 RTKI that inhibits all three VEGF receptors. This study investigated the radiosensitizing potential of CD in combination with temozolamide (TMZ) in U87 GBM xenografts expressing wtEGFR or EGFRvIII.
Radiation Research Society (RRS) 8th Annual Meeting September 25-29, Maui, HI
Effects Of Egfr Expression On Anti-Tumor Efficacy Of Vandetanib Or Cediranib Combined With Radiotherapy (Rt) In U87 Human Glioblastoma (Gbm) Xenografts, P. Wachsberger, Y. R. Lawrence, Y. Liu, A. P. Dicker
Effects Of Egfr Expression On Anti-Tumor Efficacy Of Vandetanib Or Cediranib Combined With Radiotherapy (Rt) In U87 Human Glioblastoma (Gbm) Xenografts, P. Wachsberger, Y. R. Lawrence, Y. Liu, A. P. Dicker
Bodine Journal
Introduction: Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). Cediranib is a highly potent VEGF RTKI that inhibits all three VEGF receptors. In this study we investigated the effect of exogenous overexpression of EGFR on sensitivity of human GBM U87 xenografts to vandetanib or cediranib, alone or in combination with RT.
American Association for Cancer Research (AACR) 101st Annual Meeting April 17-21, Washington, DC.